Phase II study of amsacrine and high-dose cytarabine for resistant acute myelogenous leukemia
Decker, R.W.; Ho, W.G.; Champlin, R.E.
Cancer Treatment Reports 71(9): 881-882
1987
ISSN/ISBN: 0361-5960 PMID: 3476204 Document Number: 290925
Document emailed within 1 workday
Related Documents
Miyawaki, S.; Mizoguchi, H.; Tomonaga, M.; Kanamaru, A.; Tsukagoshi, S.; Nakamura, T.; Ohashi, Y.; Yoshida, S.; Ohno, R. 1998: A phase Ii study with high-dose cytarabine (NS-075) in adult patients with relapsed and refractory acute leukemia Gan to Kagaku Ryoho. Cancer and ChemoTherapy 25(14): 2229-2242Plunkett, W.; Nowak, B.; Keating, M.J. 1987: Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy Cancer Treatment Reports 71(5): 479-483
Bassan, R.; Raimondi, R.; Lerede, T.; D'emilio, A.; Buelli, M.; Borleri, G.; Personeni, A.; Bellavita, P.; Rodeghiero, F.; Barbui, T. 1998: Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia Haematologica 83(7): 627-635
Hsu, H.C.; Chiu, C.F.; Tan, T.D.; Chau, W.K.; Tseng, C.S.; Ho, C.H. 1995: Post-remission intensive consolidation with high-dose cytarabine-based chemotherapy and granulocyte colony-stimulatory factor in adults with acute myelogenous leukemia: a preliminary report Zhonghua Yi Xue Za Zhi 56(5): 305-311
Hamaoka, R.; Jozaki, K.; Amano, T.; Itoh, H.; Imai, Y.; Nishikawa, M.; Kurokawa, M.; Yonezawa, T.; Chinen, Y. 1995: Low-dose cytarabine ocfosfate therapy in an elderly acute myelogenous leukemia Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(6): 819-822
Masaoka, T.; Ogawa, M.; Yamada, K.; Kimura, K.; Ohhashi, Y. 1993: A late phase Ii comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(13): 1995-2005
Waage, A.; Hammerstrøm, J.; Lødemel, B.; Hoff, J.E.; Langtind, J. 1986: Myelodysplastic syndrome and myelogenous leukemia. Treatment with low-dose cytarabine Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 106(6): 496-497
Arlin, Z.A.; Feldman, E.J.; Finger, L.R.; Ahmed, T.; Mittelman, A.; Cook, P.; Puccio, C.; Baskind, P.; Arnold, P.; Razis, E.D. 1991: Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia Leukemia 5(8): 712-714
Berman, E.; Arlin, Z.A.; Gaynor, J.; Miller, W.; Gee, T.; Kempin, S.J.; Mertelsmann, R.; Andreeff, M.; Reich, L.; Nahmias, N. 1989: Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol Leukemia 3(2): 115-121
Bassan, R.; Lerede, T.; Buelli, M.; Borleri, G.; Bellavita, P.; Rambaldi, A.; Barbui, T. 1998: A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia Haematologica 83(5): 422-427
Wysocki, M.; Nowaczyk-Michalak, A.; Pilecki, O.; Trybuś, L.; Balcar-Boroń, A. 1992: Jaundice following high--dose arabinoside cytosine in a child with acute myelogenous leukemia Acta Haematologica Polonica 23(3): 197-199
Jehn, U.; Heinemann, V.; Wilmanns, W. 1989: Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML) Anticancer Research 9(1): 119-124
Sutoh, H.; Yamauchi, T.; Gotoh, N.; Sugiyama, M.; Ueda, T. 2003: Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia Anticancer Research 23(6d): 5037-5042
Shlapak, D.; Kerisit, K.; Lin, C.; Wang, A.; Stumpf, B. 2013: Resident rounds. Part III: Neutrophilic eccrine hidradenitis in the setting of acute myelogenous leukemia treated with cytarabine Journal of drugs in dermatology: JDD 12(2): 231-232
Ghaddar, H.M.; Plunkett, W.; Kantarjian, H.M.; Pierce, S.; Freireich, E.J.; Keating, M.J.; Estey, E.H. 1994: Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside Leukemia 8(8): 1269-1274
Guilhot, F. 1993: Interferon alfa and low-dose cytosine-arabinoside for the treatment of patients with chronic myelogenous leukemia in chronic phase. French CML Study Group Seminars in Hematology 30(3 Suppl 3: 24-25
Archimbaud, E.; Fenaux, P.; Reiffers, J.; Cordonnier, C.; Leblond, V.; Travade, P.; Troussard, X.; Tilly, H.; Auzanneau, G.; Marie, J.P. 1993: Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia Leukemia 7(3): 372-377
Hines, J.D.; Mazza, J.J.; Oken, M.M.; Bennett, J.M.; Adelstein, D.J.; Keller, A.; O'Connell, M.J. 1985: High-dose cytosine arabinoside and mAMSA induction and consolidation in patients with previously untreated de novo acute nonlymphocytic leukemia: Phase i Pilot Study for the Eastern Cooperative Oncology Group Seminars in Oncology 12(2 Suppl 3: 117-119
Abrams, R.A.; Hanson, G.; Hansen, R.M.; Anderson, T. 1986: Phase Ii study of combination chemotherapy with etoposide and amsacrine in relapsed adult leukemia Cancer Treatment Reports 70(4): 535
Amrein, P.C.; Coleman, M.; Richards, F.; Bhardwaj, S.; Kennedy, B.J.; Haurani, F.I.; Frelick, R.W.; Pastmantier, M.W.; Herschkopf, R. 1984: Treatment of metastatic ovarian carcinoma with amsacrine: a cancer and leukemia group B phase Ii study Cancer Treatment Reports 68(11): 1397-1398